Company Overview - MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies aimed at treating cancer and other immune-mediated diseases [3] Upcoming Financial Results - The company will release its fourth quarter and year-end 2024 financial results before the market opens on March 18, 2025 [1] - MiNK executives will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results and provide a corporate update [1] Conference Call Details - Dial-in numbers for the conference call include 646-307-1963 (New York) and 800-715-9871 (USA & Canada) [2] - A live webcast and replay of the conference call will be available on the company's Events & Presentations page [2]

Core Points - MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases [1][3] - The company will release its fourth quarter and year-end 2024 financial results on March 18, 2025, before the market opens [1] - A conference call and webcast will be held at 8:30 a.m. ET on the same day to discuss the results and provide a corporate update [1][2] Company Overview - MiNK Therapeutics is advancing a pipeline of both native and next-generation engineered iNKT programs [3] - The company aims to facilitate scalable and reproducible manufacturing for off-the-shelf delivery of its therapies [3] - MiNK Therapeutics is headquartered in New York, NY, and provides information relevant to investors on its website and social media channels [3]

Core Insights - MiNK Therapeutics presented new data on its allo-iNKT cell therapy, agenT-797, demonstrating its potential to enhance immune activation in patients with refractory gastroesophageal cancer when combined with checkpoint inhibitors and chemotherapy [1][2][3] Combination Therapy Efficacy - The combination of agenT-797 with botensilimab and balstilimab showed significant immune reactivation, leading to improved clinical activity in tumors that typically do not respond to treatment [2][3] - Early induction of agenT-797 resulted in a notable increase in interferon-gamma (IFNγ) levels and enhanced tumor infiltration by T cells and antigen-presenting cells, indicating robust systemic immune engagement [3] Treatment Sequencing Importance - The most effective immune response was observed when agenT-797 was administered concurrently with checkpoint inhibitors and prior to standard chemotherapy, highlighting the significance of treatment sequencing [4] Strategic Advantages - MiNK's scalable manufacturing process allows for the generation of billions of donor-derived iNKT cells in a single run, facilitating rapid global distribution and reducing logistical challenges [6] - The company’s differentiated pipeline supports expansion into additional hard-to-treat cancers, presenting significant opportunities for growth and partnerships [6] Product Overview - AgenT-797 is designed to leverage both innate and adaptive immunity, functioning as a "master regulator" to enhance immune responses against difficult tumors [9][10] - Botensilimab and balstilimab are designed to improve anti-tumor immune responses, particularly in "cold" tumors that are less responsive to conventional therapies [11][12]

Group 1 - MiNK Therapeutics, Inc. has regained compliance with Nasdaq listing requirements, confirming it meets the minimum bid price and market value of listed securities [1] - The company specializes in the development of allogeneic invariant natural killer T (iNKT) cell therapies aimed at treating cancer and immune-mediated diseases [2] - MiNK is advancing a pipeline of both native and engineered iNKT programs, focusing on scalable and reproducible manufacturing for off-the-shelf delivery [2] Group 2 - The company is headquartered in New York, NY, and provides information relevant to investors through its website and social media channels [2] - The press release includes forward-looking statements regarding the potential benefits of iNKT cell therapies and future program goals, which are subject to various risks and uncertainties [3] - Investor and media contact information is provided for further inquiries [4]

Core Viewpoint - MiNK Therapeutics, Inc. has been selected for an oral presentation at the AACR IO Annual Meeting, showcasing interim data from its Phase 2 study of AgenT-797 in combination with botensilimab and balstilimab for treating refractory gastric cancer [1][2]. Company Overview - MiNK Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases [1][2]. - The company is advancing a pipeline of both native and engineered iNKT programs, emphasizing scalable and reproducible manufacturing for off-the-shelf delivery [2]. Product Information - AgenT-797 is an allogeneic iNKT cell therapy that combines the cytotoxic capabilities of natural killer cells with the adaptive memory of T cells, allowing for a broad range of immune responses [3]. - The product is designed to be a scalable, "off-the-shelf" cell therapy, manufactured in Lexington, MA [4]. Presentation Details - The oral presentation will focus on biomarker analysis from the Phase 2 study of AgenT-797 in combination with botensilimab and balstilimab for PD-1 refractory gastroesophageal cancer [2]. - The presentation is scheduled for February 25, 2025, from 1:00 to 1:45 p.m. PST [2].

Core Insights - MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases [1][6] - The company announced a presentation at the ASCO GI Symposium, highlighting the potential of its iNKT cell therapies in treating advanced cancers [1][5] Company Overview - MiNK Therapeutics is pioneering the discovery, development, and commercialization of iNKT cell therapies, with a focus on scalable and reproducible manufacturing for off-the-shelf delivery [6] - The company is headquartered in New York, NY, and actively engages with investors through its website and social media channels [6] Clinical Trials and Research - A Phase 2 trial is evaluating the combination of agenT-797 (iNKT cells), botensilimab, balstilimab, ramucirumab, and paclitaxel in patients with advanced gastroesophageal adenocarcinoma who have received prior therapy [8] - Previous Phase I trial data indicated long-term, durable responses and tolerability in patients with PD-1 refractory cancers, particularly in gastric cancer patients who showed significant clinical and immunologic responses [8] - MiNK plans to provide a clinical update from the ongoing Phase II study in the second half of 2025 [8] Presentation Details - The presentation at the ASCO GI Symposium will cover the Phase II study of agenT-797 in combination with other therapies for advanced gastroesophageal adenocarcinoma [5] - The session is scheduled for January 23, 2025, from 11:30 AM to 1:00 PM PST [5]

Core Insights - MiNK Therapeutics is presenting ongoing Phase 2 study results of agenT-797 for refractory gastric cancer at the ASCO GI Symposium in January 2025 [1][2] Group 1: Presentation Details - The abstract title for the presentation is "A phase II study of agenT-797 (invariant natural killer T-cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal adenocarcinoma" [2] - The presentation will take place on January 23, 2025, from 11:30 AM to 1:00 PM [2] - Complete abstracts will be released on January 21, 2025, at 5:00 PM ET [2] Group 2: Company Overview - MiNK Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases [3] - The company is advancing a pipeline of both native and next-generation engineered iNKT programs, emphasizing scalable and reproducible manufacturing for off-the-shelf delivery [3] - MiNK Therapeutics is headquartered in New York, NY, and provides investor information on its website and social media [3]

NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its third quarter 2024 financial results before the market opens on November 14, 2024. MiNK executives will host a conference call and webcast at 8 ...

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics (MiNK, NASDAQ: INKT), a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT) cell therapies, today announced the appointment of Dr. Robert Kadlec to its Board of Directors. Dr. Kadlec brings unparalleled expertise in biodefense, pandemic preparedness, and public health strategy, positioning MiNK to accelerate its innovative iNKT cell platform for addressing critical infectious diseases, ...

NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics (MiNK, NASDAQ: INKT) a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT) cell therapies and Autonomous Therapeutics, Inc. (Autonomous), a leader developing first-in-class, diseaseactivated RNA medicines, announced a research collaboration aimed at effectively targeting and treating metastatic tumors. This collaboration will leverage Autonomous' precision encrypted RNA™ (encRNA) techno ...